Jump to content

New Trial question

David Sevey

Recommended Posts

Ok so now that I have reached the end of possible treatments Stanford hospital revaluated me and I qualify for 2 phase 1 trials. 

I was told 1 was an immunotherapy and the other is a chemotherapy.  One is called JTX2011 the other is Macrogenx MGD00** I didn't write all the numbers down.

I am a little nervous due to my bad experience with immunotherapy previously.   Has anyone had experience with either of these?  I go this coming Tuesday to meet with the trial teams to decide if I am willing to go through with either trial.  

During my recent hospital stay for flu and pneumonia, I was told that my cancer has grown  a lot since my last scan




Link to comment
Share on other sites


I don't have any information other than a Jounce Theraputics press release on JTX 2011 available on "dr. google".  

ALL HANDS..... anyone with information on JTX-2011 or Macrogenex MGD phase 1 trails please chime in and give David some feedback.

Stay the course.


Link to comment
Share on other sites

Hi, David,

How did your appointment go yesterday? Please share an update when you can. LUNGevity Clinical Trial Ambassadors are volunteers available to offer information about their personal experiences with clinical trials to fellow lung cancer patients who are considering these as a treatment option. Please let me know if you'd like more information about the program and how to get connected.

With gratitude,


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.